论文部分内容阅读
目的观察不同他汀类药物治疗老年冠心病合并高胆固醇血症患者的临床效果。方法 120例老年冠心病合并高胆固醇血症患者,将其依照治疗药物分成辛伐他汀组、瑞舒伐他汀组及阿托伐他汀组,每组40例。辛伐他汀组实施辛伐他汀治疗,瑞舒伐他汀组实施瑞舒伐他汀治疗,阿托伐他汀组实施阿托伐他汀治疗,治疗结束后对比三组患者的甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)变化。结果瑞舒伐他汀组TG、TC、HDL-C及LDL-C治疗后水平分别为(1.32±0.24)、(3.55±0.42)、(1.39±0.33)及(2.10±0.32)mmol/L,辛伐他汀组为(1.33±0.29)、(4.59±0.49)、(1.25±0.35)及(2.66±0.41)mmol/L,阿托伐他汀组为(1.29±0.26)、(4.28±0.43)、(1.31±0.34)及(2.54±0.37)mmol/L(P<0.05)。治疗后三组患者的TC、TG、LDL-C较治疗前改善明显(P<0.05),瑞舒伐他汀组HDL-C较治疗前改善(P<0.05),瑞舒伐他汀组TC、TG、LDL-C、HDL-C改善水平显著优于其他两组(P<0.05),辛伐他汀组与阿托伐他汀组改善水平比较差异无统计学意义(P>0.05)。结论在他汀类药物治疗老年冠心病合并高胆固醇血症患者中,瑞舒伐他汀的临床疗效最为显著,优于辛伐他汀和阿托伐他汀治疗,值得推广。
Objective To observe the clinical effect of different statins on elderly patients with coronary heart disease complicated with hypercholesterolemia. Methods A total of 120 elderly patients with coronary heart disease complicated with hypercholesterolemia were divided into simvastatin group, rosuvastatin group and atorvastatin group according to the therapeutic drugs, 40 cases in each group. Simvastatin group was treated with simvastatin, rosuvastatin group was treated with rosuvastatin, and atorvastatin group was treated with atorvastatin. After treatment, the levels of triglyceride (TG) and triglyceride Density lipoprotein cholesterol (HDL-C), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) changes. Results The levels of TG, TC, HDL-C and LDL-C in rosuvastatin group were (1.32 ± 0.24), (3.55 ± 0.42), (1.39 ± 0.33) and (2.10 ± 0.32) mmol / L respectively (1.33 ± 0.29), (4.59 ± 0.49), (1.25 ± 0.35) and (2.66 ± 0.41) mmol / L in the statin group and (1.29 ± 0.26) and (4.28 ± 0.43) in the atorvastatin group 1.31 ± 0.34) and (2.54 ± 0.37) mmol / L respectively (P <0.05). The levels of TC, TG and LDL-C in the three groups after treatment were significantly improved (P <0.05), HDL-C in rosuvastatin group was improved (P <0.05) , LDL-C and HDL-C were significantly improved compared with the other two groups (P <0.05). There was no significant difference between the simvastatin group and the atorvastatin group (P> 0.05). Conclusions The statin treatment of elderly patients with coronary heart disease and hypercholesterolemia, rosuvastatin clinical efficacy of the most significant, better than simvastatin and atorvastatin treatment, is worth promoting.